Short answer
BIOCRYST PHARMACEUTICALS INC (BCRX) filed an 8-K current report with the SEC on August 4, 2026 reporting Item 2.05 (Costs Associated with Exit or Disposal Activities). Discovery programs discontinued and Birmingham Discovery Center of Excellence facility slated for closure.
BIOCRYST PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.05 · Costs Associated with Exit or Disposal Activities
- Discovery programs discontinued and Birmingham Discovery Center of Excellence facility slated for closure
- One-time employee termination and severance expenses estimated at $6.2–$7.5 million
- Expected cash severance expenditures of approximately $5.3–$6.6 million
- Additional facility closure costs remain unestimated, including lease termination and asset impairment charges
- Plan supports rare disease pipeline focus but creates near-term restructuring charges and cash outflows
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other BIOCRYST PHARMACEUTICALS INC 8-K filings
Get the next BCRX 8-K as it lands
Follow BCRX for push alerts, or ask the research agent what this filing means.